뒤로
eFFECTOR Therapeutics Inc(EFTR) 가격
EFTR 주가 차트
EFTR 수입
eFFECTOR Therapeutics Inc
$0
0%
$0
종가: Feb 13, 16:00:00 GMT-5
$0
0%
$0
애프터마켓: Feb 13, 21:22:13 GMT-5
최신 수익 결과: Q1 '24
보고됨: 2024-05-09
역사적 수익
분기별
연간
EPS
수익
Earnings FAQ
EFTR의 최근 주당순이익(EPS)은 예상과 비교하여 어떤가요?
eFFECTOR Therapeutics Inc EFTR의 지난 분기 매출 실적은 어땠나요?
eFFECTOR Therapeutics Inc의 매출 추정치는 얼마인가요?
eFFECTOR Therapeutics Inc의 수익 품질 점수는 얼마인가요?
eFFECTOR Therapeutics Inc는 언제 수익을 보고하나요?
eFFECTOR Therapeutics Inc의 예상 수익은 얼마인가요?
eFFECTOR Therapeutics Inc은 수익 기대치를 충족했나요?
주요 통계
이전 종가
$0.0002
시가
$0.0002
일일 범위
$0.0002 - $0.0002
52주 범위
$0.0002 - $0.01
거래량
331
평균 거래량
2.6K
EPS(TTM)
-13.31
배당수익률
--
시가총액
$940
EFTR란 무엇인가요?
eFFECTOR Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development of a new class oncology drugs known as selective translation regulator inhibitors (STRIs). The company is headquartered in Solana Beach, California and currently employs 14 full-time employees. The company went IPO on 2021-01-08. The firm is focused on the development of oncology drugs, such as selective translation regulator inhibitors (STRIs). The firm uses a selective translation regulation technology platform to internally discover a portfolio of small molecule STRI product candidates. Its product candidates target the eIF4F complex and its activating kinase, MNK. The Company’s lead product candidate, tomivosertib, is an inhibitor of MNK, and is being evaluated in combination with KEYTRUDA (pembrolizumab), an FDA-approved inhibitor of programmed cell death protein 1 (PD-1) in a randomized Phase 2b clinical trial in patients with metastatic non-small cell lung cancer (NSCLC). Its second product candidate, zotatifin, is an inhibitor of eIF4A, a component of the eIF4F complex, and is being evaluated in a Phase 1/2 clinical trial in patients with certain solid tumors. Its third program is focused on developing inhibitors of eIF4E.